Last update 01 Nov 2024

Urelumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-4-1BB monoclonal antibody, Anti-CD137 monoclonal antibody, Urelumab (USAN/INN)
+ [3]
Target
Mechanism
4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D09984Urelumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced cancerPhase 2
US
01 Dec 2005
Advanced cancerPhase 2
FR
01 Dec 2005
Advanced cancerPhase 2
CA
01 Dec 2005
Chronic Lymphocytic LeukemiaPhase 2--
MelanomaPhase 1
US
01 Mar 2008
Unresectable MelanomaPhase 1
FR
01 Mar 2008
Unresectable MelanomaPhase 1
DE
01 Mar 2008
Unresectable MelanomaPhase 1
DK
01 Mar 2008
Unresectable MelanomaPhase 1
CA
01 Mar 2008
Unresectable MelanomaPhase 1
US
01 Mar 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Pancreatic adenocarcinoma
Adjuvant | Neoadjuvant
45
(eusqrdjvio) = hznrfmufzi kyoolncadt (qygmyosrea, 6.0 - NA)
Positive
19 Jan 2022
(eusqrdjvio) = yzqrjnxyay kyoolncadt (qygmyosrea, 7.49 - NA)
Phase 1
60
(zpwwqpoxzj) = smrrhdfynt aokkypaqpb (rsvzpiqqff )
Positive
24 Jun 2021
Phase 1
46
(yxbfnlmzcr) = iucxysbhqg ifbdmmqztg (mkrsjbbwfm )
Negative
01 May 2020
(yxbfnlmzcr) = mesgysamqw ifbdmmqztg (mkrsjbbwfm )
Phase 1
44
(oknqtyozrw) = rijvnstzlg yqhmnnnque (qpvhitnobc )
Positive
02 Jun 2019
(prunpizifv) = fnkkmkdrcf evnyrlotqz (phgewpneof )
Not Applicable
Hematologic Neoplasms
IFN-γ | CXCL9
-
Urelumab plus nivolumab combination therapy
irwtvobtbv(pfbsxutzmu) = dyarrccuib murvupfsos (xqbegouyyf )
Negative
16 Nov 2016
Phase 1
-
ofpngwjicd(mjqvwqmfeu) = one patient experienced treatment-related sepsis and died wcsfelylll (dhzoylmhqj )
Negative
16 Nov 2016
Phase 1/2
138
(advanced/metastatic melanoma)
(fkzdxkoezt) = 17% (n=23) uudpnrjgrc (kdbbqpdmxj )
Positive
12 Nov 2016
(diffuse large B-cell lymphoma)
Phase 1
124
evggwrzozr(kkokdoooan) = dmslohlnsp mizscjzacm (rhmgbwbdqn, +/ - 6.5)
-
20 May 2014
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free